• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bayer, Evotec partner on kidney diseases treatments

Bayer, Evotec partner on kidney diseases treatments

September 21, 2016
CenterWatch Staff

Bayer and Evotec have entered into a five-year, multi-target research partnership to develop multiple clinical candidates for the treatment of kidney diseases such as chronic kidney disease in diabetes patients. Both companies will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options for these severe conditions. The partners will share responsibilities during preclinical development of potential clinical candidates.

"Chronic kidney disease is a severe medical condition with insufficient treatment options for many patients. This new research alliance with Evotec will perfectly complement Bayer's current research activities in this area of high unmet medical need," said Professor Andreas Busch, member of the executive committee of Bayer's Pharmaceuticals Division and head of Drug Discovery. "Evotec is already a strong partner of ours, and we look forward to continuing the relationship to develop novel drug candidates for the benefit of patients."

Dr. Cord Dohrmann, chief scientific officer of Evotec, said, "This research alliance will particularly target chronic kidney diseases, which are the leading cause of end-stage renal disease. Currently, patients with end-stage renal disease face dialysis or kidney transplantation as the only available treatment options. There are no effective treatments that can significantly slow or reverse disease progression. We are very proud and excited to expand our efforts in kidney diseases together with Bayer in this area of enormous unmet medical need."

Bayer will receive exclusive access to selected candidates as well as to Evotec's CureNephrontarget pipeline. Bayer will be responsible for any subsequent clinical development and commercialization. Evotec will receive a minimum of €14 million over the contract period including research payments and an undisclosed license fee. In addition, Evotec is eligible to receive pre-clinical, clinical and sales milestones of potentially over € 300 m as well as tiered royalties up to low double-digit percentage of net sales.

In 2012, Bayer and Evotec entered into a five-year partnership in the therapeutic area of endometriosis. Currently in its fourth year, this alliance has delivered four preclinical candidates and one first-in-class clinical program has been initiated.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing